Dr Reddys Laboratories (RDY) Asset Writedowns and Impairment (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Asset Writedowns and Impairment for 8 consecutive years, with $1.0 million the latest figure, recorded in Q2 2023.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.0 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $8.0 million (changed N/A YoY) and the FY2026 annual result came in at $38.0 million, up 90.0% from the prior year.
• Asset Writedowns and Impairment declined to $1.0 million in Q2 2023 per RDY's latest filing, from $7.0 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for RDY reached as high as $185.0 million in Q3 2019 and fell as low as $2.0 in Q3 2022.
• A 5-year average of $55.8 million and a median of $11.0 million in 2020 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2020 — Asset Writedowns and Impairment sank 78.0% — and 2021, when it changed 0.0%.
• Year by year, Asset Writedowns and Impairment stood at $185.0 million in 2019, then declined by 2.16% to $181.0 million in 2020, then tumbled by 93.92% to $11.0 million in 2021, then slumped by 36.36% to $7.0 million in 2022, then slumped by 85.71% to $1.0 million in 2023.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.0 million, $7.0 million, and $2.0 for Q2 2023, Q4 2022, and Q3 2022 respectively.